Biogen PRO logo
  • Content library
    • Alzheimer's & Neurodegenerative Diseases
    • Clinical Assessment
    • Fluid Biomarkers
    • Imaging
    • Management of ARIA
    • Biostatistics
    • Case Studies
    • Treatment
  • Congresses
    • BiogenAD symposium​
    • AD Symposium Comprehensive Cognitive Assessment 2020 CA
    • AD Symposium Evaluating Pathological Biomarkers 2020 CA ​
    • AD Symposium Healthcare System Readiness 2020 CA​
    • AD Symposium Case Study2020 CA​
    • Preparing the health system: where do we go from here?
    • Leveraging biomarkers for an earlier diagnosis of AD
    • The challenges we face in advancing the AD clinical and research landscape
    • Pursuing a memory complain: how do we better detect and refer patients earlier?
  • Learning Programs
  • Other Resources
  • Cookies
  • Subscribe
    • Thank you
  • Expert Perspectives
    • To what extent do you believe the guidelines presented (WHO and Lancet Commission) will have an impact on clinical practice in Alzheimer’s disease?
    • What is the most important scientific update in terms of advancing the AD field from AAIC, and why?
    • What is your key takeaway for the Alzheimer’s disease community from AAIC?
    • What updates from AAIC do you consider to have the greatest impact on your clinical practice, and why?
    • What updates from CTAD do you consider to have the greatest impact on your clinical practice, and why? Perspectives from Dr. Sophie Auriacombe
    • What updates from CTAD do you consider to have the greatest impact on your clinical practice, and why? Perspectives from Dr. John Morgan
    • What is your key takeaway for the Alzheimer's disease community from CTAD? Perspectives from Jill Rasmussen
    • What is your key takeaway for the Alzheimer's disease community from CTAD? Perspectives from Dr. Collin Liu
  • To what extent do you believe the guidelines presented (WHO and Lancet Commission) will have an impact on clinical practice in Alzheimer’s disease?
  • What is the most important scientific update in terms of advancing the AD field from AAIC, and why?
  • What is your key takeaway for the Alzheimer’s disease community from AAIC?
  • What updates from AAIC do you consider to have the greatest impact on your clinical practice, and why?
  • What updates from CTAD do you consider to have the greatest impact on your clinical practice, and why? Perspectives from Dr. Sophie Auriacombe
  • What updates from CTAD do you consider to have the greatest impact on your clinical practice, and why? Perspectives from Dr. John Morgan
  • What is your key takeaway for the Alzheimer's disease community from CTAD? Perspectives from Jill Rasmussen
  • What is your key takeaway for the Alzheimer's disease community from CTAD? Perspectives from Dr. Collin Liu

Stay Connected

Sign-up with us for continuous access to updated information, learning content and upcoming events to help you better understand and manage Alzheimer’s disease.

Sign-up

Content library

  • Alzheimer's & Neurodegenerative Diseases
  • Clinical
    Assessment
  • Fluid
    Biomarkers
  • Imaging
  • Management of ARIA
  • Case Studies
  • Biostatistics

Congresses

Learning Programs

Other Resources

  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Unsubscribe
  • Cookies

© 2022 Biogen. All rights reserved.
This site is intended for healthcare professionals practicing in Canada.

All trademarks are the property of their respective owners
Biogen-61606